Ivabradine: Pharmacodynamic aspects of its clinical use

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 30, Issue 8, 2008, Pages 633-641

  Stieber, Juliane ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Angina; HCN channels; Heart rate; Ivrabradine; Pacemaker current

Indexed keywords

ATENOLOL; CARRIER PROTEIN; HYPERPOLARIZATION ACTIVATED CYCLIC NUCLEOTIDE GATED CHANNEL; IVABRADINE; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE TITRATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SPECIFICITY; DRUG STRUCTURE; HEART ARRHYTHMIA; HEART PROTECTION; HEART RATE; HUMAN; NONHUMAN; PHARMACODYNAMICS; PROTEIN FUNCTION; RECOMMENDED DRUG DOSE; REVIEW; STABLE ANGINA PECTORIS;

ANGINA PECTORIS; ANIMALS; BENZAZEPINES; CHRONIC DISEASE; CYCLIC NUCLEOTIDE-GATED CATION CHANNELS; HEART RATE; HUMANS; ION CHANNELS;

EID: 59249108973     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: 10.1358/mf.2008.30.8.1268816     Document Type: Review

References (47)

1. Singh, B.N. Classes of antianginal compounds: Old and new - Therapeutic implications. J Cardiovasc Pharmacol Ther 2003, 8(2): 85-8.
2. Benetos, A., Rudnichi, A., Thomas, F., Safar, M., Guize, L. Influence of heart rate on mortality in a French population: Role of age, gender, and blood pressure. Hypertension 1999, 33(1): 44-52.
3. Ferrari, R., Cargnoni, A., Ceconi, C. Anti-ischaemic effect of ivabradine. Pharmacol Res 2006, 53(5): 435-9.
4. Yusuf, S., Camm, A.J. Sinus tachyarrhythmias and the specific bradycardic agents: A marriage made in heaven? J Cardiovasc Pharmacol Ther 2003, 8(2): 89-105.
5. Ludwig, A., Stieber, J., Moosmang, S., Herrmann, S., Biel, M., Hofmann, F. HCN channels: From genes to function. In: Cardiac Electrophysiology: From Cell to Bedside, 4th Ed. Zipes, D., Jalife, J. (Eds.). Saunders (Elsevier), Philadelphia, 2004, 59-65.
6. Baruscotti, M., Bucchi, A., DiFrancesco, F. Physiology and pharmacology of the cardiac pacemaker ("funny") current. Pharmacol Ther 2005, 107(1): 59-79.
7. DiFrancesco, D. Serious workings of the funny current. Prog Biophys Mol Biol 2006, 90(1-3): 13-25.
8. Robinson, R., Siegelbaum, S. Hyperpolarization-activated cation currents: From molecules to physiological function. Annu Rev Physiol 2003, 65: 453-80.
9. Brown, H., DiFrancesco, D. Voltage-clamp investigations of membrane currents underlying pacemaker activity in rabbit sinoatrial node. J Physiol 1980, 308: 331-51.
10. Camm, A., Tendera, M. Heart rate slowing by If current inhibition. Adv Cardiol, Vol. 43. Basel, Karger, 2006.
11. Bucchi, A., Baruscotti, M., DiFrancesco, D. Current-dependent block of rabbit sinoatrial node If channels by ivabradine. J Gen Physiol 2002, 120(1): 1-13.
12. DiFrancesco, D. Funny channels in the control of cardiac rhythm and mode of action of selective blockers. Pharmacol Res 2006, 53(5): 399-406.
13. Sorbera, L.A., Castañer, J. Ivabradine hydrochloride. Drugs Fut 2003, 28(7): 652-8.
14. Thollon, C., Bidouard, J.P., Cambarrat, C. et al. Stereospecific in vitro and in vivo effects of the new sinus node inhibitor (+)-S 16257. Eur J Pharmacol 1997, 339(1): 43-51.
15. Vilaine, J.P. The discovery of the selective If current inhibitor ivabradine. A new therapeutic approach to ischemic heart disease. Pharmacol Res 2006, 53(5): 424-34.
16. Ludwig, A., Zong, X.-G., Jeglitsch, M., Hofmann, F., Biel, M. A family of hyperpolarization-activated mammalian cation channels. Nature 1998, 393(6685): 587-91.
17. Santoro, B., Liu, D., Yao, H. et al. Identification of a gene encoding a hyperpolarization-activated pacemaker channel of brain. Cell 1998, 93(5): 717-29.
18. Ishii, T.M., Takano, M., Xie, L.-H., Noma, A., Ohmori, H. Molecular characterization of the hyperpolarization-activated cation channel in rabbit heart sinoatrial node. J Biol Chem 1999, 274(18): 12835-9.
19. Bucchi, A., Tognati, A., Milanesi, R., Baruscotti, M., DiFrancesco, D. Properties of ivabradine-induced block of HCN1 and HCN4 pacemaker channels. J Physiol 2006, 572(Pt. 2): 335-46.
20. Stieber, J., Wieland, K., Stoeckl, G., Ludwig, A., Hofmann, F. Bradycardic and proarrhythmic properties of sinus node inhibitors. Mol Pharmacol 2006, 69(4): 1328-37.
21. Ludwig, A., Budde, T., Stieber, J. et al. Absence epilepsy and sinus dysrhythmia in mice lacking the pacemaker channel HCN2. EMBO J 2003, 22(2): 216-24.
22. Strauss, U., Kole, M., Bräuer, A. et al. An impaired neocortical Ih is associated with enhanced excitability and absence epilepsy. Eur J Neurosci 2004, 19(11): 3048-58.
23. Deisz, R., Spilker, L., Strauss, U., Lehmann, T.-N., Bohr, K. Cellular mechanism of hyperexcitability in cortical slices from epilepsy surgery. Z Epileptol 2003, 16: 214-22.
24. Cervetto, L., Demontis, G.C., Gargini, C. Cellular mechanisms underlying the pharmacological induction of phosphenes. Br J Pharmacol 2007, 150(4): 383-90.
25. Procoralan - European summary of product characteristics. From Les Laboratoires Servier, France. Available at: http://www.servier.com.
26. European Medicines Agency. EPARs for authorized medicinal products for human use: European Public Assessment Report 2005 - Procoralan. Available at: http://www.emea.europa.eu/human-docs/Humans/EPAR/ procoralan/procoralan.htm.
27. Stieber, J., Herrmann, S., Feil, S. et al. The hyperpolarization-activated channel HCN4 is required for the generation of pacemaker action potentials in the embryonic heart. Proc Natl Acad Sci USA 2003, 100(25): 15235-40.
28. Delpon, E., Valenzuela, C., Perez, O. et al. Mechanisms of block of a human cloned potassium channel by the enantiomers of a new bradycardic agent: S-16257-2 and S-16260-2. Br J Pharmacol 1996, 117(6): 1293-301.
29. Perez, O., Gay, P., Franqueza, L. et al. Effects of the two enantiomers, S-16257-2 and S-16260-2, of a new bradycardic agent on guinea-pig isolated cardiac preparations. Br J Pharmacol 1995, 115(5): 787-94.
30. Bois, P., Bescond, J., Renaudon, B., Lenfant, J. Mode of action of bradycardic agent, S 16257, on ionic currents of rabbit sinoatrial node cells. Br J Pharmacol 1996, 118(4): 1051-7.
31. DiFrancesco, D., Camm, J.A. Heart rate lowering by specific and selective If current inhibition with ivabradine. Drugs 2004, 64(16): 1757-65.
32. Joannides, R., Moore, N., Iacob, M. et al. Comparative effects of ivabradine, a selective heart rate-lowering agent, propranolol on systemic and cardiac haemodynamics at rest and during exercise. Br J Clin Pharmacol 2005, 61(2): 127-37.
33. Mangin, L., Swynghedauw, B., Benis, A., Thibault, N., Lerebours, G., Carré, F. Relationship between heart rate and heart rate variability: Study in conscious rats. J Cardiovasc Pharmacol 1998, 32(4): 601-7.
34. François-Bouchard, M., Simonin, G., Bossant, M.-J., Boursier-Neyret, C. Simultaneous determination of ivabradine and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Biomed Sci Appl 2000, 745(2): 261-9.
35. Borer, J.S., Fox, K., Jaillon, P., Lerebours, G.; for the Ivabradine Investigators Group. Antianginal and anti-ischemic effects of ivabradine, an If inhibitor, in stable angina. Circulation 2003, 107(6): 817-23.
36. Tardif, J.-C., Ford, I., Tendera, M., Bourassa, M.G., Fox, K.; for the INITIATIVE Investigators. Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005, 26(23): 2529-36.
37. Fox, K., Ferrari, R., Tendera, M., Steg, P.G., Ford, I.; on behalf of the BEAUTIFUL Steering Committee. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: The morbidity-mortality evaluation of the If inhibitor ivabradine in patients with coronary disease and left ventricular dysfunction (BEAUTIFUL) study. Am Heart J 2006, 152(5): 860-6.
38. Fox, K., Ford, I., Steg, P.G., Tendera, M., Ferrari, R.; BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left ventricular dysfunction (BEAUTIFUL) : A randomized, double-blind, placebo-controlled trial. Lancet 2008, 372(9641): 807-16.
39. Albaladejo, P., Carusi, A., Apartian, A., Lacolley, P., Safar, M.E., Bénétos, A. Effect of chronic heart rate reduction with ivabradine on carotid and aortic structure and function in normotensive and hypertensive rats. J Vasc Res 2003, 40(4): 320-8.
40. Mulder, P., Barbier, S., Chagraoui, A. et al. Long-term heart rate reduction induced by the selective If current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation 2004, 109(13): 1674-9.
41. Manz, M., Reuter, M., Lauck, G., Omran, H., Jung, W. A single intravenous dose of ivabradine, a novel If inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology 2003, 100(3): 149-55.
42. Cerbai, E., Barbieri, M., Mugelli, A. Characterization of the hyperpolarization-activated current, If in ventricular myocytes isolated from hypertensive rats. J Physiol 1994, 481(Pt. 3): 585-91.
43. f) and hyperpolarization-activated cyclic nucleotide-gated channel mRNA expression in ventricular cells from control and hypertrophied rat hearts. J Physiol 2003, 553(Pt. 2): 395-405.
44. Cerbai, E., Pino, R., Porciatti, F. et al. Characterization of the hyperpolarization-activated current, If in ventricular myocytes from human failing heart. Circulation 1997, 95(3): 568-71.
45. Hoppe, U., Jansen, E., Sudkamp, M., Beuckelmann D. Hyperpolarization-activated inward current in ventricular myocytes from normal and failing human hearts. Circulation 1998, 97(1): 55-65.
46. Stilli, D., Sgoifo, A., Macchi, E. et al. Myocardial remodeling and arrhythmogenesis in moderate cardiac hypertrophy in rats. Am J Physiol Heart Circ Physiol 2001, 280(1): H142-50.
47. Bel, A., Perrault, L.P., Faris, B., Mouas, C., Vilaine, J.P., Menasché, P. Inhibition of the pacemaker current: A bradycardic therapy for off-pump coronary operations. Ann Thorac Surg 1998, 66(1): 148-52.